Radioprotectant Stabilization of Mitogenic Lectins During Electron Beam Sterilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Radiation sterilization techniques, such as electron beam radiation, significantly diminish the biological activity of biologically active proteins like phytohemagglutinin (PHA) used in immunological assays, leading to decreased production efficiency and increased production costs due to the need for higher raw material inputs to compensate for lost bioactivity.
Innovation Solution
Contacting biologically active proteins with soluble radioprotectant compounds like cysteine, melatonin, or glutathione before radiation sterilization to form a radioprotected mixture, which is then sterilized, thereby preserving and stabilizing the biological activity of the proteins during and after the process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation sterilization is applied to biologically active proteins, then sterilization effectiveness is improved, but biological activity is significantly diminished
Solution Approach 1:
A radioprotectant compound is introduced as an intermediary substance that mediates between the radiation sterilization process and the biologically active protein. The radioprotectant absorbs or mitigates the harmful effects of radiation on the protein, allowing sterilization to occur while preserving biological activity. This intermediary approach resolves the contradiction by adding a protective agent that enables both sterilization effectiveness and biological activity retention.
Solution Approach 2:
The patent modifies the chemical environment parameters by adjusting pH, ionic strength, and radioprotectant concentration to optimize protein stability during radiation exposure. By changing these physical-chemical parameters, the protein becomes more resistant to radiation-induced damage while maintaining its biological function, thus resolving the contradiction between sterilization and activity preservation.
2Productivity
If higher raw material inputs are used to compensate for lost bioactivity, then production efficiency is improved, but production costs increase
Solution Approach 1:
The radioprotectant is added to the protein formulation before the radiation sterilization process occurs. This preliminary protective action prevents bioactivity loss in advance, eliminating the need for compensatory increases in raw material inputs. By performing protection beforehand, the patent maintains production efficiency without increasing material costs.
Solution Approach 2:
The patent converts the harmful effect of radiation into a beneficial outcome by using the radioprotectant to selectively protect the protein while allowing sterilization to proceed. The radiation, which would normally damage the protein, becomes an effective sterilization method when combined with the radioprotectant, thereby improving production efficiency without requiring additional raw materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of radioprotectant compounds effectively protects the biological activity of proteins against radiation damage, maintaining or even enhancing their activity post-sterilization and during storage, reducing the need for increased raw material inputs and associated costs.
Implementation Method 1
contacting the biologically active protein or other biologically active molecule in an aqueous solution with at least one soluble radioprotectant compound to obtain a radioprotected mixture prior to radiation sterilization
Data Source
AI summary
Compositions and methods are disclosed that relate to protecting biological activity of a biologically active molecule, including a biologically active protein or biological response modifier such as an immune response modifier, against radiation damage during radiation sterilization. Inclusion of at least one radio-protectant compound, for example, cysteine, reduced glutathione, melatonin, and/or histidine, in an exemplary mitogenic lectin formulation during spray-drying onto surfaces of immunoassay tubes, surprisingly protected the lectin against loss of biological (mitogenic) activity that would otherwise result from electron beam radiation sterilization. The radioprotectant compound also protected other biologically active molecules and stabilized their biological activities, permitting them to retain biological activity after extended storage following the radiation treatment.